Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

Description

This trial aims to study the efficacy and safety of cannabidivarin (CBDV) in children with ASD.

Conditions

Autism Spectrum Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

This trial aims to study the efficacy and safety of cannabidivarin (CBDV) in children with ASD.

Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

Condition
Autism Spectrum Disorder
Intervention / Treatment

-

Contacts and Locations

Bronx

Montefiore Medical Center, Bronx, New York, United States, 10467

New York

New York University (NYU) Langone, New York, New York, United States, 10016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    5 Years to 18 Years

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Montefiore Medical Center,

    Eric Hollander, MD, PRINCIPAL_INVESTIGATOR, Montefiore Medical Center/Albert Einstein College of Medicine

    Study Record Dates

    2025-12